124 related articles for article (PubMed ID: 30377764)
1. Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry.
Chen Z; Deng X; Ye Y; Gao L; Zhang W; Liu W; Zhao S
Ann Hematol; 2019 Feb; 98(2):391-399. PubMed ID: 30377764
[TBL] [Abstract][Full Text] [Related]
2. Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma.
Zhu Q; Deng X; Yao W; Chen Z; Ye Y; Gao L; Zhang W; Liu W; Zhao S
Ann Hematol; 2021 Mar; 100(3):715-723. PubMed ID: 33389024
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study.
Xu Y; Kroft SH; McKenna RW; Aquino DB
Br J Haematol; 2001 Mar; 112(4):945-9. PubMed ID: 11298589
[TBL] [Abstract][Full Text] [Related]
4. Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma.
Chen Z; Deng X; Ye Y; Zhang W; Liu W; Zhao S
Front Oncol; 2021; 11():687911. PubMed ID: 34211855
[TBL] [Abstract][Full Text] [Related]
5. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
6. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
7. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
List AF; Spier CM; Miller TP; Grogan TM
Leukemia; 1993 Mar; 7(3):398-403. PubMed ID: 7680400
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
9. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8
Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A
J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024
[TBL] [Abstract][Full Text] [Related]
10. Low Level of Blood CD4
Judd J; Dulaimi E; Li T; Millenson MM; Borghaei H; Smith MR; Al-Saleem T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):83-88. PubMed ID: 28027895
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of T lymphocytes infiltration in breast cancer].
Yu HM; Jiao SC; Yang JL; Wang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
[TBL] [Abstract][Full Text] [Related]
12. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
Pollari M; Pellinen T; Karjalainen-Lindsberg ML; Kellokumpu-Lehtinen PL; Leivonen SK; Leppä S
Eur J Haematol; 2020 Dec; 105(6):712-721. PubMed ID: 32632935
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
14. High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma.
Chang C; Wu SY; Kang YW; Lin KP; Chen TY; Medeiros LJ; Chang KC
Am J Clin Pathol; 2015 Dec; 144(6):935-44. PubMed ID: 26573001
[TBL] [Abstract][Full Text] [Related]
15. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
17. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
[TBL] [Abstract][Full Text] [Related]
19. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
20. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]